© 2018 Miraculo Inc. All Rights Reserved
Cannabinoids are a group of chemicals derived from the marijuana plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and it is said to have anti inflammatory effects on animal cells. Tetrahydrocannabinol (THC) is another one of these chemicals that produces a psychoactive effect in the brains of the animals who have taken it. Cannabinoid receptors are located in the endocannabinoid system and allow cannabinoids to bind and work in the body. This paper has set out to evaluate current evidence of cannabis having a therapeutic potential to treat a range of human disorders.
Here is the full scientific article if you wish to download it.
Cannabinoids may have a therapeutic potential
Research papers from 1997 regarding cannabinoids and human diseases were selected for this study to compare and contrast their therapeutic potential. 15 clinical trials were selected and 3 of these trials had over 100 patients each. 2 of these trials discovered that cannabinoids were better than placebo in controlling muscle stiffness arising from multiple sclerosis (MS). Some of these patients with MS claimed that motor improvement had increased with use of cannabinoids. In smaller trials, cannabinoids paved way for improvement of tics from tourettes disease and headaches. CBD’s, which are non psychoactive, had a massive impact in chronic pain in that it therapeutically eased the patients said pain.
More studies are needed
Studies have shown that there were no significant improvements were made in levodopa-induced dyskinesia in Parkinson’s disease or post parkinson’s surgery. Cachexia treatment with CBD’s was the exact same as placebo treatment. Quality of life was improved for 3 trials out of 15. Synthetic cannabinoids may be good for certain conditions that lack efficient treatments such as muscle stiffness, tics and neuropathic pain. Medical cannabis could potentially develop into drugs for cannabinoid therapy because of their little side effects, however more studies with bigger clinical trial sizes are needed, especially with active placebo.